This meeting took place in the past. For a complete list of the meetings for the upcoming/current season, see our meeting list or click on related meetings tab below to check for related meeting(s).
Web Desc
Ubiquitin Signaling
joint with NF-kappaB Signaling and Biology: From Bench to Bedside
Organizer(s): Ivan Dikic and Raymond J. Deshaies
Date: March 18 - 23, 2012
Location: Whistler Conference Centre, Whistler, BC, Canada
Supported by the Directors' Fund
Summary of Meeting:
Post-translational modifications of cellular proteins by ubiquitin and ubiquitin-like modifiers regulate a variety of functions in the cell. A crucial aspect of signaling through ubiquitin and Ubls is the presence of modular binding domains that recognize particular types of ubiquitin signals. Such molecular coupling creates an attractive “decoding” mechanism for responding to alterations in the cellular microenvironment and regulating physiological and pathophysiological conditions. In this meeting, we will discuss the major challenges in the field including detection of endogenous ubiquitination events, functional aspects of novel types of ubiquitin chains and their recognition by selective binding domains, and high-throughput technologies for comprehensive analysis of Ub modifications. The intersection between the deregulated ubiquitin signaling, pathogenesis of human diseases and therapies targeting the Ub system will be explored. The program offers a possibility for young scientists to present their own work and engage in discussions on the emerging topics in the field. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on NF-kB Signaling and Biology: From Bench to Bedside, which will share a keynote address and three plenary sessions with this meeting.
Scholarship Deadline: November 16 2011
Discounted Abstract Deadline: November 16 2011
Abstract Deadline: December 20 2011
Discounted Registration Deadline: January 18 2012
We gratefully acknowledge additional support for this conference from:
Boston Biochem, an R&D Systems CompanyCell Signaling Technology, Inc.
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Genentech, Inc.

Millennium Pharmaceuticals, Inc., The Takeda Oncology Company
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found